Table 2.
Clinical trials of immune checkpoint inhibitors in the maintenance setting after first-line platinum chemotherapy for metastatic urothelial carcinoma.
| Regimen | Drug Classes | Trial Name | Phase | Status (March 2023) |
Identifier |
|---|---|---|---|---|---|
| Nivolumab + Ipilimumab | Anti-PD1 + Anti-CTLA4 | VEXILLUM | 2 | Recruiting | NCT05219435 |
| Avelumab + Talazoparib | Anti-PDL1 + PARP inhibitor | TALASUR | 2 | Recruiting | NCT04678362 |
| Avelumab + Lurbinectedin | Anti-PDL1 + chemotherapy | 2 | Recruiting | NCT05574504 | |
| Avelumab + Copanlisib | Anti-PDL1 + PI3K inhibitor | 1/2 | Not yet recruiting | NCT05687721 | |
| Avelumab + MRx0518 | Anti-PDL1 + Enterococcus gallinarum | AVENU | 2 | Withdrawn | NCT05107427 |
| Avelumab + Trilaciclib | Anti-PDL1 + CDK4/6 inhibitor | PRESERVE 3 | 2 | Active, not recruiting | NCT04887831 |
| Avelumab +/− SG or M6223 or NKTR-255 | Anti-PDL1 +/− ADC or anti-TIGIT or IL-15 receptor agonist | JAVELIN Bladder Medley | 2 | Recruiting | NCT05327530 |
| Cohort 4: Cisplatin + SG → maintenance SG + either Avelumab or Zimberelimab Cohort 5: Zimberelimab +/− SG vs. Avelumab |
Chemo + ADC then ADC + PD1 or PDL1 Anti-PD1 +/− ADC |
TROPHY U-01 | 2 | Recruiting | NCT03547973 |
| Avelumab +/− Cabozantinib | Anti-PDL1 + multi-TKI | MAIN-CAV | 3 | Recruiting | NCT05092958 |
Abbreviations: SG = Sacituzumab govitecan; ADC = antibody–drug conjugate; TKI = tyrosine kinase inhibitor.